A 10-year holding period changes the way investors should think about growth shares.
The focus shifts away from short-term price movements and toward businesses that can keep expanding earnings through different market conditions.
That usually means looking for companies with strong competitive positions, scalable models, and long runways for growth.
With that in mind, here are three high-quality ASX growth shares that could be worth buying and holding for the next decade.
Image source: Getty Images
CAR Group Ltd (ASX: CAR)
The first ASX growth share to consider buying is CAR Group.
It owns digital vehicle marketplaces in Australia and several international markets. Its flagship platform, carsales, is one of the strongest online classified businesses in the country.
The appeal of CAR Group is its marketplace structure. Buyers want to use the platform with the most listings, while dealers and private sellers want to advertise where the buyers are. This creates a network effect that is difficult for competitors to break.
The company has also expanded beyond Australia, giving it access to larger offshore markets. That international exposure provides another path for earnings growth over time.
With strong platform economics and a long history of execution, CAR Group remains well placed to keep compounding over the next decade.
ResMed Inc (ASX: RMD)
ResMed is another high-quality ASX growth share that could reward patient investors.
It is a global leader in sleep apnoea treatment and respiratory care. Its devices, masks, and connected software help patients manage breathing-related conditions at home.
The long-term opportunity is supported by a large underdiagnosed market. Millions of people globally suffer from sleep apnoea, but the majority remain untreated. As awareness improves and healthcare systems focus more on home-based care, demand for ResMed's products should continue to grow.
The company also benefits from scale, brand trust, and an expanding digital ecosystem. Connected devices and software give ResMed a stronger relationship with patients, providers, and healthcare systems.
With strong long-term healthcare demand and a leadership position in its market, ResMed has the qualities needed to keep growing well into the future.
TechnologyOne Ltd (ASX: TNE)
TechnologyOne is a third ASX growth share to look at this month.
It offers a different type of long-term growth opportunity. The company provides enterprise software to government departments, councils, universities, and large organisations. These customers rely on its products for critical operations, which supports high retention and recurring revenue.
TechnologyOne's shift to software-as-a-service has strengthened the business. It has improved revenue visibility, supported margins, and given the company a more scalable platform for growth.
Its expansion opportunity is also not limited to Australia. The company has been building its presence in the United Kingdom, which could become a more meaningful contributor over time if execution remains strong.
With mission-critical software, recurring revenue, and a disciplined growth strategy, TechnologyOne could be a share to own for the next 10 years.
